Citi lowered the firm’s price target on Cencora (COR) to $355 from $405 and keeps a Buy rating on the shares. The company reported “disappointing” U.S. healthcare results in fiscal Q2.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora reports Q2 adjusted EPS $4.75, consensus $4.73
- Cencora raises FY26 adjusted EPS view to $17.65-$17.90 from $17.45-$17.75
- Midday Fly By: Disney, AMD, CVS report quarterly beats
- Cencora Earnings Call: Profit Strength Amid Revenue Reset
- Cencora lifts 2026 outlook after OneOncology-fueled earnings jump